公海555000官网

Dec 08, 2025｜2025
Henlius Unveils Multi-Disciplinary Research on Serplulimab at ESMO Asia, Demonstrating Broad Clinical Value

    The 2025 European Society for Medical Oncology Asia (ESMO Asia 2025) Congress were held in Singapore from December 5–7, 2025. At this conference, latest results from seven studies on Henlius’ innovative anti-PD-1 monoclonal antibody, HANSIZHUANG (serplulimab, Hetronifly® in Europe) were released. These studies span lung cancer, gastrointestinal tumors, squamous cell carcinoma, and gynecological cancer, underscoring the extensive clinical value of serplulimab.

   

    Serplulimab is the world’s first anti-PD-1 monoclonal antibody(mAb) approved for the first-line treatment of small cell lung cancer (SCLC), and the only anti-PD-1 mAb to have succeeded in a Phase 3 perioperative registration study in gastric cancer. To date, serplulimab has been approved for the treatment of squamous NSCLC (sqNSCLC), extensive-stage SCLC (ES-SCLC), esophageal squamous cell carcinoma (ESCC), and non-squamous NSCLC (nsqNSCLC). It has been approved in over 40 countries and regions including China, the U.K., Germany, Singapore and India, covering nearly half of the global population and accelerating global accessibility. Serplulimab demonstrates unique advantages in treating various solid tumors via its differentiated mechanism, especially achieving groundbreaking progress in both lung and gastric cancers. The drug not only induces stronger PD-1 internalization—reducing PD-1 receptor presence on T cells for rapid and potent immune activation [1]—but also minimizes PD-1-mediated recruitment of the co-stimulatory molecule CD28, thereby preserving CD28 signaling [2-4], enhancing downstream AKT activity [5], and promoting sustained T-cell activation.

   

    In lung cancer, serplulimab has covered the full range of first-line treatment. Beyond its three approved indications (sqNSCLC, ES-SCLC, nsqNSCLC), Henlius is conducting a global, multicenter Phase 3 trial of serplulimab plus chemotherapy and radiotherapy for first-line treatment of limited-stage SCLC (LS-SCLC).  Additionally, bridging studies for ES-SCLC are underway in both the U.S. and Japan, with patient enrollment for the head-to-head bridging study in the U.S. already completed. In the field of gastrointestinal cancers, the company continues to deepen its clinical exploration of serplulimab. In addition to the approved indication for ESCC, the phase 3 clinical trial of serplulimab plus chemotherapy as neoadjuvant/adjuvant therapy for gastric cancer has met its primary endpoint. As the world-first regimen in gastric cancer that replaces adjuvant chemotherapy with mono-immunotherapy in the perioperative setting, serplulimab has been granted breakthrough therapy designation by the Center for Drug Evaluation (CDE) of China. Besides, an international, multicenter Phase 3 trial (ASTRUM-015) of serplulimab in combination with bevacizumab and chemotherapy as first-line therapy for metastatic colorectal cancer (mCRC) is being simultaneously advanced in multiple countries worldwide.

   

    At this ESMO Asia conference, latest results from prospective IIT studies on serplulimab in treating MSS-type metastatic colorectal cancer (mCRC) and locally advanced head and neck squamous cell carcinoma (HNSCC) have been released, demonstrating preliminary efficacy and potential clinical benefits of immunotherapy combination therapy. Besides, latest results from IIT studies assessing serplulimab in HER2-positive advanced gastric cancer were also published at the conference. Real-world research data related to serplulimab further validated its efficacy in first-line treatment of advanced sqNSCLC and explored its prospects for neoadjuvant therapy in locally advanced NSCLC and treatment of cervical cancer.

   

    #Squamous Cell Carcinoma

    Title: Induction Serplulimab and Cetuximab Combined with Chemotherapy Followed by Radiotherapy for Unresectable Locally Advanced HNSCC: A Single-arm, Prospective, Phase II Study

    Results: This single-arm, prospective, phase II study enrolled patients with confirmed unresectable LA-HNSCC (excluding nasopharyngeal carcinoma). Patients received serplulimab (4.5 mg/kg, Q3W) + cetuximab (400 mg/m2 loading, followed by 250 mg/m2, QW) + liposomal paclitaxel (135 mg/m2, D1) + cisplatin (75 mg/m2, Q3W), for 3 weeks per cycle, with 2 total treatment cycles. Definitive radiotherapy was administered following the induction therapy. From Sep 2024 to Jun 2025, this study enrolled 9 patients with a median age of 67 years (range, 54-72), with 88.9% having a history of smoking. The most common primary tumor site was the hypopharynx (44.4%). After two cycles of induction therapy, both the ORR and DCR reached 100.0% (95% CI 66.4–100.0), including five patients (55.6%) who achieved a complete response (CR), and no cases of progressive disease (PD) were observed. Following evaluation, 77.8% of patients proceeded to receive radical radiotherapy. The most frequently observed grade ≥3 treatment-related adverse event (TRAE) was myelosuppression, occurring in 33.3% of patients. No unexpected or treatment-related fatal adverse events were observed, and the survival data remain immature at this stage.

    Conclusion: In patients with unresectable LA-HNSCC, this induction regimen showed preliminary efficacy and manageable toxicity. Further follow-up is required to confirm the survival benefit.

   

   

    #Gastrointestinal Tumors

    Title: A Multicenter Randomized Trial of Serplulimab After mFOLFOX6 and HLX04 Induction in First-Line Treatment of MSS Metastatic Colorectal Cancer

    Results: This prospective, multicenter, randomized controlled trial enrolled treatment-naïve patients(pts) with MSS unresectable mCRC. Pts were randomized 1:1 to receive mFOLFOX6 plus HLX04 (bevacizumab biosimilar), with or without the addition of serplulimab (PD-1 inhibitor) after two induction cycles. Pts who achieved disease control after 4-6 months treatment would enter maintenance stage. As of Aug 1st, 2025, 19 pts had been enrolled, including 10 pts receiving serplulimab. Pts in serplulimab arm had a higher baseline tumor burden versus control arm.  Despite this, the serplulimab arm achieved better efficacy in PFS (7.2 months vs 6.1 months), and it also showed a higher 6-month PFS rate (87.5% vs 59.3%); Additionally, the serplulimab arm achieved better efficacy in ORR (90% vs 77.7%), and DCR (90% vs 77.7%).Multiplex immunohistochemistry (mIHC) analysis also revealed a post-treatment decrease in CD4 + Treg cells（CD3+CD4+Foxp3+）.

    Conclusion: This preliminary analysis suggests that first-line induction with mFOLFOX6 and HLX04, followed by the addition of serplulimab, may provide clinical benefit in MSS mCRC. mIHC data offers unique insights of tumor microenvironment.

   

   

    Title: Updated outcome and ctDNA Profiling in Advanced HER2+ Gastric Cancer Patients Treated with DOS plus Serplulimab and Trastuzumab: A Phase II Multicenter Trial 

    Results:This Phase II trial (NCT05311189) enrolled 40 unresectable/metastatic HER2+ gastric cancer patients (July 2022–September 2024) treated with intensive chemotherapy plus PD-1 and HER2 blockade. Among the 37 evaluable patients (median follow-up: 12.57 months(m)), the median progression-free survival (PFS) was 15.7 months (95% CI: 10.2 m to not reached). Among those with blood samples, 14 responders (Durable Clinical Benefit, DCB) and 14 non-responders(Non-durable Benefit, NDB) were stratified by a 12-month response duration cutoff. Overall, reduction of TGAs (SNVs and ERBB2 CN) , tumor fraction (TF), mutant allele frequency (MSAF), and blood-based tumor mutation burden (bTMB) were observed in C2D1 in plasma from enrolled patients.

    Conclusion: DOS with plus S and T displayed sustained anti-tumor activity. ctDNA dynamics, especially blood ERBB2 CN hold substantial clinical utility for evaluating clinical outcomes in advanced HER2+ gastric cancer.

   

   

    Title: Identification of Potential Immune Biomarkers associating to Clinical Benefit from Intensive Chemotherapy Combined with Serplulimab and Trastuzumab in Advanced HER2+ Gastric Cancer: A Post-hoc Analysis of the ASTRUM Study

    Results: 40 pts enrolled (Jul 2022 – Sep 2024) received S (4.5 mg/kg Q3W), T (8 mg/kg → 6 mg/kg Q3W), and DOS chemo (oxaliplatin, docetaxel, S-1). Durable Clinical Benefit(DCB, n=16) and Non-durable Benefit(NDB, n=15) were defined by ≥ 12-month response. DCB tumors showed upregulation of CCL19/21, CD19/79, CXCL9/11, and CD28, indicating an immune-active profile. Pathway enrichment revealed B/T-cell activation, IFN-γ response, and antigen presentation. CD8⁺ T cells, B cells, TIS, and TLS were significantly increased and correlated with clinical benefit.

    Conclusion: Integrated tumour and circulating immune signatures forecast durable efficacy of treatment. baseline immune biomarkers serve as putatively predictive biomarkers for clinical benefit.

   

    #Lung Cancer

    Title: Real-World Study of Serplulimab as First-Line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer

    Results: We included patients with advanced sqNSCLC diagnosed via pathological or cytological examination and ineligible for surgery or radiotherapy. These patients received first-line treatment with serplulimab at the First Affiliated Hospital of Nanchang University between 2022 and 2024. All patients completed at least two cycles of serplulimab treatment. A total of 46 patients with advanced sqNSCLC were enrolled, including 27 with stage III and 19 with stage IV disease. The median age was 67 years (range: 41–86), and the median follow-up duration was 12 months (range: 1.47–24.63). Disease progression occurred in 21 patients (21/46, 45.65%), with a median PFS of 11.0 months (95% CI, 10.00–NR). The 1-year and 2-year PFS rates were 48.21% (95% CI, 33.66–69.06) and 27.39% (95% CI, 12.53–59.9), respectively. No statistically significant factors influencing PFS were identified in subgroup analyses. Among the treated patients, 27 achieved partial response (PR), resulting in an ORR of 58.70% (95% CI, 43.23–73.00). 1-year OS rate was 85.21% (95% CI, 73.75–98.46). AEs were reported in 22 patients (22/46, 47.83%), with no treatment-related deaths observed.

    Conclusion: In this real-world study, serplulimab exhibited remarkable efficacy and a well-tolerated safety profile, supporting its use as a highly effective first-line immunotherapy option for advanced sqNSCLC.

   

   

    Title: Efficacy and Safety of Neoadjuvant Serplulimab in Locally Advanced Driver Gene-Negative NSCLC: A Multicenter Real-World Study

    Results: This prospective study enrolled patients with histologically confirmed, locally advanced NSCLC and no actionable genomic alterations. Patients received at least 1 cycle of neoadjuvant serplulimab (300 mg, Q3W) plus platinum-based chemotherapy, followed by definitive surgery. From Jan 2022 to Dec 2024, 27 patients (median age, 64 years) were enrolled, including 81.5% (22/27) with stage III disease. Among these patients, R0 resection was achieved in 92.6% (25/27). Pathological assessment revealed an MPR rate of 74.1% (20/27) and a pCR rate of 33.3% (9/27). Radiographically, 2 complete responses (CR) and 20 partial responses (PR) were observed, yielding an ORR of 81.5% (22/27; 95% CI, 61.9–93.7%) and a DCR of 96.3% (26/27; 95% CI, 81.0–99.9%). Exploratory biomarker analysis indicated that MPR was associated with higher baseline lymphocyte counts (P=0.003) and lower post-neoadjuvant neutrophil-to-lymphocyte ratio (NLR;P=0.035). At a median follow-up of 9.1 months (range 2.9–24.7), 4 EFS events occurred (including 1 death). Treatment-related adverse events (TRAEs) occurred in 37.0% (10/27), with grade ≥3 TRAEs in 7.4% (2/27).

    Conclusion: Neoadjuvant serplulimab-chemotherapy demonstrated promising efficacy and manageable toxicity in real-world locally advanced NSCLC. Survival outcomes require longer follow-up to assess clinical benefit.

   

   

    #Gynaecological Cancer

    Title: Serplulimab in Advanced, Recurrent, or Metastatic Cervical Cancer: A Prospective Multicenter Real-World Study

    Results: Eligible patients (aged ≥18 years) with advanced, recurrent, or metastatic cervical cancer were treated with serplulimab as monotherapy or in combination with other therapies in the post-initial settings. A total of 33 patients with advanced, recurrent, or metastatic cervical cancer were enrolled, with a median age of 60 years. Among the 27 patients evaluable for tumor response, two achieved a complete response (CR), and 15 achieved a partial response (PR), resulting in an ORR of 63.0% (95% CI, 42.4–80.6%) and a DCR of 92.6% (95%CI, 75.7–99.1%). PFS events occurred in 16 patients, with a median PFS of 8.6 months (95% CI, 7.0–NR). In multiple subgroup analyses, including comparisons between immunotherapy alone and immunotherapy combinations, no significant differences in PFS were observed. However, the addition of anti-angiogenic therapy to immunochemotherapy prolonged the median PFS by 2.5 months compared to regimens without anti-angiogenic agents (11.6 vs. 9.1 months). During the study period, two deaths were reported. A total of 23 patients (69.7%) experienced any grade adverse events (AEs), and three patients (9.1%) reported grade ≥ 3 treatment-related AEs. The incidence of AEs was lower in the immunotherapy monotherapy group compared to the combination immunotherapy group (60.0% vs. 77.8%).

    Conclusion: Serplulimab demonstrated significant efficacy and a manageable safety profile in patients with advanced, recurrent, or metastatic cervical cancer. The absence of significant differences in efficacy observed in the subgroup analysis further indicates that serplulimab is a promising treatment option for patients with advanced, recurrent, or metastatic cervical cancer in the post-initial settings.

   

   

   

    【Reference】


    [1] Issafras H, et al. Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy. PLoS One. 2021;16(12):e0257972.


    [2] Hui E, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017;355(6332):1428-1433.


    [3] Patsoukis N, et al. Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation. Commun Biol. 2020;3(1):128.


    [4] Fenwick C, et al. Tumor suppression of novel anti-PD-1 antibodies mediated through CD28 costimulatory pathway. J Exp Med. 2019;216(7):1525-1541.


    [5] Primavera E, et al. Computer-Aided Identification of Kinase-Targeted Small Molecules for Cancer: A Review on AKT Protein. Pharmaceuticals (Basel). 2023;16(7):993.



Back
Privacy Policy
Cookies Policy
Accessibility
Terms of Use
Privacy Policy

Introduction

 

Shanghai Henlius Biotech, Inc., and, where applicable, its affiliates and subsidiaries (collectively, “we” , “us” or “our”) attach great importance to the protection of your privacy and personal information. This Privacy Notice (this “Policy”) is formulated in accordance with applicable PRC laws and regulations governing the protection of personal information in the People’s Republic of China (“PRC”).

 

This Policy applies when: (1) you browse or use our website and other online resources (such as our WeChat official accounts); (2) subscribe to our news or announcements; or (3) contact us through the contact details or other interactive features made available on our website, or otherwise interact with us through our website.. The purpose of this Policy is to explain how and why we process your personal information, the types of personal information involved, applicable retention periods, your rights, and the measures we take to protect personal information. Please read this Policy carefully to ensure that you fully understand its content.

 

In certain business scenarios, we may provide additional explanations regarding the processing of your personal information through separate agreements, privacy statements, or personal information notices. In the event of any inconsistency, such documents shall prevail. For example, where a recruitment function is provided through a third-party platform or service, the relevant third party privacy policy or notice may also apply.

 

For the purposes of this Policy, “personal information” refers to all kinds of information related to identified or identifiable natural persons, excluding anonymized information.

 

We collect, use, store, transfer and otherwise process personal information in strict compliance with applicable PRC laws and regulations of the People’s Republic of China.

 

Our website may contain links to third party websites for your convenience. We do not control, and are not responsible for, the privacy practices of such third parties. We encourage you to review their privacy policies before using those websites.

 

If you have any questions or concerns regarding this Policy or our processing of personal information, please contact us using the details provided below.

 

This Policy will help you understand:

 

I. How we collect your personal information

 

II. How we use your personal information

 

III. How we entrust, share, transfer and publicly disclose your personal information

 

IV. Cross border transfer of personal information

 

V. How we store your personal information

 

VI. Security measures

 

VII. Your rights

 

VIII. Personal information of minors

 

IX. Updates to this Policy

 

X. How to contact us

 

I. How do we collect your personal information?

 

In addition to our employees, we may process personal information of the following persons:

 

• Visitors and users of our website;

 

• Healthcare Professionals;

 

• Investigators of clinical trial institutions and personnel of contract research organizations in clinical trials;

 

• Subjects of clinical trials and their relatives;

 

• Consumers/patients and their relatives using our products or services;

 

• Staff of business partners (including vendors, distributors, partners, etc.); and

 

• Our applicants.

 

We may process personal information of website visitors and individuals who contact or interact with us through our website or other online resources. Depending on the relevant page, function, or interaction, separate privacy notices, consents, platform privacy policies, contracts, or other notices may apply.

 

Based on the context in which you interact with us, we may collect personal information by the following means and on the legal bases permitted by applicable PRC laws and regulations, including your consent, the necessity for entering into or performing a contract, compliance with legal obligations, protection of life, health or property, public health needs, or other circumstances permitted by law:

 

• Your personal information provided to us voluntarily

 

When you subscribe to our news or announcements, contact us through the contact details or other interactive features made available on our website, a third-party platform or service linked or referred to on our website, or otherwise communicate with us in relation to our website, we may collect the personal information that you voluntarily provide, such as your name, contact details, organization, and the content of your inquiry or request, depending on the relevant page or function.

 

• Personal information collected by us independently through our website and other online channels

 

When you visit our website, most of our services do not require any registration, and you can visit our website without telling us who you are. However, some pages or functions may require you to provide certain personal information. If you choose not provide such information as we request, you may not be able to access certain content or functions or we may not be able to respond to your inquiry, request or subscription. Please refer to the relevant page or notice for further details about the categories of personal information collected in a specific scenario.

 

• Personal information we collect from vendors or business partners

 

In the course of our daily business operations, we may collect personal information from our vendors or business partners. We require our vendors and business partners to comply with the requirements of the personal information protection laws and regulations of the PRC and to lawfully provide us with personal information. If you are an employee or representative of one of our vendors or business partners, we may collect personal information such as your name and contact details for the purpose of establishing business contacts and cooperations.

 

• Personal information we collect from publicly available sources

 

We may collect personal information of medical and healthcare professionals from such publicy available sources, such as the official websites of medical institutions and the official websites of competent government departments, and process such information within a reasonable scope and for lawful purposes. For example, for the purpose of lawful academic or professional interaction with healthcare professionals, we may collect the name, gender, employer, position, practitioner registration information, academic title, degree, educational background, specialty expertise, and profile information, where such information has been lawfully made public.

 

Our website may include links, contact details, QR codes, or references to third-party platforms or services. Where you choose to interact with us through such third-party platforms or services, the relevant third party may also process your personal information in accordance with its own privacy policy and applicable law, and we encourage you to review such policy before submitting your information.

 

II. How do we use your personal information?

 

We may use your personal information for the following purposes:

 

• Operating, maintaining and improving our website and other online resource;

 

• Researching, developing, providing and continuously improving our products and services;

 

• Conducting and managing daily business;

 

• Academic interaction with healthcare professionals;

 

• Responding to your inquiries, requests, or communications sent through our website or the contact details made available on our website;

 

• Providing subscription services for our news, announcements, or investor-related updates;

 

• Managing and maintaining our relationship and communications with business contacts who reach us through our website;

 

• Recruiting and human resource management;

 

• Internal compliance management，audit，record-keeping; and

 

• Complying with applicable PRC laws and regulations, for example, monitoring and reporting adverse events for purposes of performing drug quality management responsibilities, providing medical information and dealing with product complaints, etc..

 

We will process personal information only to the extent necessary for the relevant purpose. Where required by applicable law, we will obtain your consent or separate consent before processing your personal information or sensitive personal information. Where a third-party platform or service is used in connection with a particular function, the relevant third party may process your personal information in accordance with its own privacy policy and applicable law.

 

III. How do we entrust, share, transfer and publicly disclose your personal information?

 

1. Entrustment

 

We may entrust our business partners with the processing of your personal information for the purpose(s) described in this Policy. We will enter into appropriate confidentiality, data processing and security agreements with such entrusted parties and require them to process personal information in accordance with our instructions , this Policy and applicable PRC laws and regulations.

 

2. Sharing and public disclosure

 

For the purpose(s) described in this Policy, we will share or publicly disclose your personal information only where permitted by applicable PRC laws and regulations and, where required, after obtaining your consent or separate consent. Such circumstances may include:

 

• Sharing your personal information among our affiliates and subsidiaries where necessary for legitimate business, management, compliance, or operational purposes;

 

• Sharing your personal information with vendors or business partners (such as conference service providers, travel service providers, data service providers, banking or insurance institutions, other professional service organizations, to the extent necessary for the relevant purpose); and

 

• Disclosing your personal information to the extent that it is permitted or required by applicable PRC laws and regulations or for the purpose of assisting with investigations by judicial, regulatory or law enforcement authorities.

 

• other circumstances permitted by applicable PRC laws and regulations.

 

If you submit your information through or in connection with a third-party platform or service referred to on our website, the relevant third party may independently process your personal information in accordance with its own privacy policy and applicable law.

 

3. Transfer

 

We will not transfer your personal information to any other company, entity or individual unless otherwise permitted by applicable law and, where required, after obtaining your consent. Further, in the event of a merger, acquisition, insolvency, reorganization, division, dissolution, bankruptcy, or similar transaction, we will require the new processor of your personal information to continue to be bound by this Policy or we will require the new processor to obtain your consent again.

 

IV.How do we provide your personal information across borders?

 

In principle, personal information that we collect and generate in the course of our operations within the territory of the PRC will be stored within the PRC. In certain circumstances, it may be necessary for us to provide your personal information to recipients outside the PRC in connection with our business operations, website functions, or communications, where permitted by applicable PRC laws and regulations. As required by applicable laws and regulations regarding the protection of personal information, we will provide you with the required notice and obtain your separate consent before providing your personal information across any border, unless otherwise permitted by law. We will use lawful cross-border transfer mechanisms to transfer your personal information oversea and will take necessary measures to ensure that the oversea recipients provide a level of protection required by applicable PRC laws and regulations.

 

You may obtain more information about cross-border transfers of personal information and oversea recipients through the contact methods referred to in this Policy.

 

V. How do we store your personal information?

 

We will retain your personal information for the minimum period necessary to achieve the purposes described in this Policy ,unless a longer retention period is required or permitted by applicable PRC laws and regulations. Upon expiration of the applicable retention period, we will promptly delete or anonymize your personal information in accordance with applicable PRC laws and regulations. Our criteria for determining the period for which personal information shall be retained include:

 

• Applicable laws, regulations and other relevant requirements;

 

• The period of time needed for us to provide services, maintain business relations or interact with you; and

 

• The period of time needed for us to perform relevant agreements or fulfil the purposes described in this Policy.

 

VI. What security measures do we take to protect your personal information?

 

In accordance with applicable PRC laws, regulations, and the requirements of relevant national standards, we take reasonable and appropriate security and precautionary measures to protect the personal information we process against unauthorized access, public disclosure, use, modification, destruction or loss of data. However, you are also responsible for taking appropriate measures to protect the security of the devices, systems, and networks you use when accessing our website or communicating with us.

 

VII. Your rights 

 

In accordance with the requirements of the applicable PRC laws and regulations, you may have the following rights in respect of your personal information:

 

• To know about and make decisions regarding the processing of your personal information;

 

• To access or copy your personal information;

 

• To correct or supplement your personal information;

 

• To delete your personal information;

 

• To request for explanation of rules regarding processing of personal information; and

 

• To change the scope of your consent or revoke your consent , where processing is based on your consent.

 

If you wish to exercise your rights with respect to personal information, you may contact us through the contact information listed in this Policy and we will respond to any request in accordance with applicable relevant laws and regulations. When you exercise the above rights, we may verify your identity to safeguard the security of your personal information. Subject to applicable PRC laws and regulations, there may be circumstances where we are unable to respond to all or part of your request.

 

VIII. How do we process the personal information of minors?

 

For the purposes of this Policy and in accordance with applicable PRC laws and regulations, our products, websites and services are not targeted at minors under the age of 14. Minors under the age of 14 should not provide personal information to us without the consent of a parent or legal guardian.

 

If a minor's personal information is collected with the consent of a parent or legal guardian, we will process the information only when permitted by law, with the express consent of the parent or legal guardian, or necessary for the protection of the minor. If we discover that we have collected personal information without obtaining verifiable prior consent of a parent or legal guardian, we will seek to delete the data as soon as possible.

 

IX. Updates of the Policy

 

We may revise our Privacy Policy from time to time. We will post the updated version on our website and update the “Last Updated” date above or below this Policy.

 

Last updated: March 30, 2026.

 

X. How to contact us?

 

If you have any questions, comments or suggestions concerning this Policy, or any questions or concerns about our processing of your personal information, you may contact us in the following ways:

 

Address: 11/F, B8 Building, No.188 Yizhou Rd, Xuhui District, Shanghai

 

Tel.: 021- 33395800

 

Postal Code: 200233

 

Email: PR@178xian.com

 

Cookies Policy

When you visit our website, we may place small data files known as “cookies” on your device. Cookies enable our website to recognize your browser and help us understand how visitors use the site.

 

Cookies and similar technologies used on this website may collect online identifiers, device information, browser information, IP address, and information about how you interact with the website. In certain circumstances, such information may constitute personal information or may be associated with you under applicable PRC laws and regulations. Information collected through cookies is used for purposes such as ensuring website operation, maintaining security, analyzing traffic and performance, remembering user preferences, and improving website content and user experience.

 

You may choose to accept or decline cookies by adjusting your browser settings or through any cookie banner or preference center made available on our website, if applicable. Please note that disabling cookies may affect the functionality of certain parts of the website.

 

For more information about how we process personal information, please refer to our Privacy Notice.

 

Some cookies may be provided by third parties. Where third-party cookies or similar technologies are used, such third parties may process the relevant information in accordance with their own privacy policies and applicable PRC laws and regulations.

Accessibility

Shanghai Henlius Biotech, Inc. (“Henlius”) is committed to improving the accessibility and user friendliness of its website for all visitors.

 

We strive to ensure that the content on our website can be accessed and used by individuals with diverse needs, including those who rely on assistive technologies. As our website continues to evolve, we recognize that accessibility is an ongoing effort, and we are continuously working to improve usability and accessibility across our digital platforms.

 

If you experience difficulty accessing any part of our website, or have suggestions on how we can enhance accessibility, we welcome your feedback. To help us respond effectively, please include the specific webpage address (URL) and a brief description of the issue encountered.

 

Contact us:

Email: PR@178xian.com

(Please include “Website Accessibility” in the subject line)

Henlius will make reasonable efforts to review accessibility-related feedback and improve the overall online experience for all users. While we strive to improve accessibility, we do not guarantee that every page or feature will be fully accessible to every user in all circumstances.

Terms of Use

This website (http://www.178xian.com/) is developed and operated by Shanghai Henlius Biotech, Inc. (“Henlius”). Please read these Terms of Use carefully before accessing or using this website. By accessing, browsing or using this website, you acknowledge that you have read, understood and agreed to be bound by these Terms of Use and applicable PRC laws and regulations.

 

Henlius reserves the right to modify or update these Terms of Use at any time. Any updated version will be posted on this website with a revised “Last Updated” date. Please review them periodically for updates.

 

Prohibited Conduct:

 

You shall not infringe the lawful rights and interests of Henlius or any third party, nor interfere with or attempt to interfere with the normal operation, security, or integrity of this website by any means. Without limitation, you shall not use this website for any unlawful purpose, attempt unauthorized access to any part of the website or related systems, introduce malicious code, scrape or extract website content through automated means, or otherwise interfere with the website’s operation or security features.

 

Copyright

 

All content on this website, including but not limited to text, data, logos, graphics, audio, video and other materials, is owned by Henlius or its respective rights holders, unless otherwise stated. Such content is protected by applicable Chinese and international copyright laws. This website and its content may be accessed and used only for lawful, personal, and non-commercial purposes. Without prior written consent, no entity or individual may copy, reproduce, republish, upload, post, transmit, distribute, modify, create derivative works from, mirror, or otherwise use such content for commercial or public purposes.

 

Disclaimers

 

To the fullest extent permitted by applicable PRC laws and regulations, Henlius makes no warranties or representations, express or implied, regarding the content of this website, including but not limited to accuracy, completeness, timeliness or suitability for any particular purpose. Henlius does not undertake any obligation to update the content of this website , except as otherwise required by applicable PRC laws and regulations.

 

You use this website and any information obtained from it at your own risk. To the fullest extent permitted by applicable PRC laws and regulations, Henlius shall not be liable for any loss or damage arising from the use or inability to use this website, including but not limited to system failures, computer viruses or data loss.

 

Medical Information

 

Nothing on this website constitutes medical advice, diagnosisor treatment recommendations. Medical decisions should always be made in consultation with qualified healthcare professionals. Any product-related or disease-related information provided on this website is provided for general informational purposes only and should not be construed as medical advice, diagnosis, or treatment recommendations; any product information is subject to the approved prescribing information and applicable local laws and regulations.

 

Third Party Websites

 

This website may contain links to third party websites for convenience. Henlius is not responsible for the content, availability, privacy practices, terms or use of such third-party websites. Access to third party websites is at your own risk.

 

Privacy

 

Henlius respects your privacy. Please refer to our Privacy Notice for details.

 

Governing Law

 

These Terms of Use shall be governed by the laws of the People’s Republic of China.

 

Last updated: March 30, 2026